Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: A meta-analysis

JAMA Cardiology

Volumn 2, Issue 6, 2017, Pages 685-688

  Al Khatib, Sana M ^a   Fonarow, Gregg C ^b   Joglar, Jose A ^c   Inoue, Lurdes Y T ^d   Mark, Daniel B ^a   Lee, Kerry L ^e   Kadish, Alan ^f   Bardy, Gust ^g   Sanders, Gillian D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DATA QUALITY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MEDICAL SOCIETY; META ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; NONISCHEMIC CARDIOMYOPATHY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SUDDEN CARDIAC DEATH; VALIDITY; CARDIOMYOPATHY; HEART FAILURE; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MORTALITY; PROPORTIONAL HAZARDS MODEL;

CARDIOMYOPATHIES; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; MORTALITY; PRIMARY PREVENTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85026447143     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.0630     Document Type: Article

References (7)

1. Kadish A, Dyer A, Daubert JP, et al; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-2158.
2. Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237.
3. Epstein AE, DiMarco JP, Ellenbogen KA, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J AmColl Cardiol. 2013;61(3):e6-e75.
4. Køber L, Thune JJ, Nielsen JC, et al; DANISH Investigators. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-1230.
5. Bänsch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453-1458.
6. Chin KL, Skiba M, Tonkin A, et al. The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Heart Fail Rev. 2016;21(6):675-697.
7. Golwala H, Bajaj NS, Arora G, Arora P. Implantable cardioverter-defibrillator for non ischemic cardiomyopathy: an updated meta-analysis. Circulation. 2017;135(2):201-203.